Who Brands - Brand Ownership DirectoryWho Brands
HomeBrowse BrandsCategoriesCompaniesCompareBlogQuizAbout
HomeBrowse BrandsCategoriesCompaniesCompareBlogQuizAbout
Who Brands

Your trusted reference for brand ownership information. We provide factual, comprehensive data about who owns the brands you know.

Stay in the know

Get the latest ownership updates delivered to your inbox.

Browse

  • All Brands
  • Categories
  • Companies
  • Countries
  • Compare Brands
  • Blog
  • Brand Quiz
  • RSS Feed

Company

  • About Us
  • Methodology
  • Contact
  • FAQ
  • Submit a Brand
  • List Your Brand
  • Write for Us

Legal

  • Terms of Service
  • Privacy Policy
  • Cookie Policy
  • Affiliate Disclosure
  • Disclaimer

Support Us

☕Buy me a coffee

2026 Who Brands. All information is provided for educational purposes. Brand names and logos are trademarks of their respective owners.

  1. Home
  2. Brands
  3. Healthcare & Pharmaceuticals
  4. Nurtec ODT
Nurtec ODT logo
Healthcare & Pharmaceuticals

Who Owns Nurtec ODT?

Nurtec ODT is owned by Pfizer Inc. (NYSE: PFE), a publicly traded American pharmaceutical company headquartered in New York City. Pfizer obtained Nurtec through its October 2022 acquisition of Biohaven Pharmaceutical for approximately $11.6 billion. Nurtec ODT (rimegepant) is a CGRP receptor antagonist first FDA approved in February 2020 for acute migraine treatment.

Parent Company

Pfizer Inc.

Acquired

2022

Status

Publicly Traded

Headquarters

New York, New York, USA

Nurtec ODT Timeline

1849
Pfizer Inc.

Parent company established in New York, New York, USA

Company Founded
2020

Nurtec ODT

Founded by Biohaven Pharmaceutical (original development)

Founded
2022
Acquired by Pfizer Inc.

Pfizer Inc. acquired Nurtec ODT

Acquired
United StatesOfficial Website

Who Owns Nurtec ODT?

  • Parent Company: Pfizer Inc.
  • Ownership Type: Product line
  • Acquisition Year: 2022
  • Company Type: Publicly Traded
  • Stock Ticker: NYSE: PFE
BrandParent CompanyOwnership Type
Nurtec ODTPfizer Inc.Product line

Where to Buy

Disclosure: We may earn commission from purchases
AmazonNurtec ODT on Amazon

History of Nurtec ODT

  • Founded: 2020
  • Founders: Biohaven Pharmaceutical (original development)
  • Acquired by Pfizer Inc.: 2022

Rimegepant originated in Bristol-Myers Squibb's research programs on calcitonin gene-related peptide antagonists, a mechanism identified decades ago as central to migraine pathophysiology. BMS deprioritized the compound, and Biohaven, a Connecticut-based biotech founded by Vladimir Coric and colleagues in 2013, licensed it along with the broader CGRP portfolio and pushed it into late-stage development.

Biohaven's trials demonstrated that rimegepant could treat acute migraine attacks and, taken every other day, also prevent them, a dual indication unusual among migraine therapies. The FDA approved Nurtec ODT for acute migraine treatment in February 2020, a launch complicated by the arrival of the COVID-19 pandemic within weeks of approval, which forced Biohaven to build commercial traction largely through digital marketing and telehealth when physician detailing was restricted.

The preventive indication was added in May 2021, making Nurtec the only CGRP oral agent approved for both acute treatment and prevention. The drug's orally disintegrating tablet format, designed for patients who cannot swallow during attacks, differentiated it from competitors including AbbVie's Ubrelvy.

Pfizer acquired Biohaven for approximately $11.6 billion in October 2022, a deal driven primarily by the Nurtec franchise and the CGRP pipeline. The non-CGRP Biohaven assets were spun out to shareholders as a separate company, Biohaven Ltd., retaining the neuroscience pipeline while Pfizer took the migraine business. Under Pfizer, Nurtec has been integrated into a commercial infrastructure vastly larger than Biohaven's, expanding its prescriber reach and international filings.

About Pfizer Inc.

What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.

Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.

Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.

Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.

How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.

Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.

What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

  • Founded: 1849
  • Headquarters: New York, New York, USA
  • Company Type: Publicly Traded
  • Stock: NYSE: PFE
  • Revenue: $62.6 billion (FY2025)
  • Employees: approximately 88,000

Visit Pfizer Inc. website

View full company profile for Pfizer Inc.

Where Is Nurtec ODT Made / Based?

  • Headquarters: New York, New York, USA
  • Manufacturing / Operations: United States

Nurtec ODT Categories & Tags

MigraineCgrp InhibitorNeurologyPrescription DrugHeadache Treatment

Nurtec ODT Recalls & Controversies

Nurtec's public record is relatively clean. The drug's main reported adverse events include nausea and hypersensitivity reactions labeled in the prescribing information, with post-marketing surveillance ongoing as for all newer agents.

Controversy at the corporate level touched the Biohaven acquisition indirectly: Biohaven's founders and its scientific claims around the broader pipeline attracted short-seller skepticism during its independent years, questions that became Pfizer's to absorb when it bought the CGRP business. The spin-out structure, which left the non-migraine assets outside Pfizer, was itself a debated transaction structure in biotech coverage.

No product recall has occurred. Pricing follows the brand-name pharmaceutical norm and has drawn the standard criticism applied to new migraine therapies costing hundreds of dollars per dose pack before insurance.

Brands Owned by Pfizer Inc.

AbrysvoHealthcare Pharmaceuticals

Abrysvo

Owned by Pfizer Inc.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

rsv-vaccinevaccinesmaternal-immunization
AdcetrisHealthcare Pharmaceuticals

Adcetris

Owned by Pfizer Inc.

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.

oncologyantibody-drug-conjugatelymphoma
CaduetHealthcare Pharmaceuticals

Caduet

Owned by Pfizer Inc.

Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.

prescription-drugcardiovascularhypertension
CelebrexHealthcare Pharmaceuticals

Celebrex

Owned by Pfizer Inc.

Prescription COX-2 inhibitor anti-inflammatory medication for treating arthritis pain, originally developed by G.D. Searle & Company and now marketed by Pfizer.

pain-reliefanti-inflammatoryarthritis
ChantixHealthcare Pharmaceuticals

Chantix

Owned by Pfizer Inc.

Prescription smoking cessation medication (varenicline) developed by Pfizer, FDA-approved in 2006.

smoking-cessationvareniclinenicotinic-receptor
ComirnatyHealthcare Pharmaceuticals

Comirnaty

Owned by Pfizer Inc.

Pfizer-BioNTech COVID-19 mRNA vaccine, the first FDA-approved COVID vaccine in the United States, co-commercialized globally by Pfizer and BioNTech.

covid-19mrna-vaccinevaccines
View all brands owned by Pfizer Inc.

Nurtec ODT Ownership: Pros & Cons

Advantages

  • +Pfizer's commercial infrastructure dramatically expanded prescriber reach after the Biohaven deal
  • +Only oral CGRP antagonist approved for both acute treatment and prevention
  • +Orally disintegrating format addresses a real clinical need during migraine attacks
  • +Migraine market size provides room for continued class growth

Considerations

  • -Pfizer paid approximately $11.6 billion for a franchise that must now justify the premium
  • -Injectable CGRP monoclonals compete for the preventive segment with strong efficacy data
  • -Acute treatment market share is contested directly by AbbVie's Ubrelvy
  • -Patent expiry timelines will eventually open the product to generic competition

Frequently Asked Questions About Nurtec ODT

Sources & Further Reading

  • Nurtec ODT Website
  • Pfizer Investor Relations
  • Pfizer-Biohaven Acquisition Announcement
  • FDA Approval: Nurtec ODT
  • SEC EDGAR: Pfizer Filings
  • Wikidata: Rimegepant

Competitors to Nurtec ODT

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

BrandParent CompanyCountryFoundedMarket PositionPrimary MarketGender Target
ExelonExelon
Novartis
Switzerland
1997
Mass marketGlobalAll Genders

Learn More About Competitors

ExelonHealthcare Pharmaceuticals

Exelon

Owned by Novartis

Brand name for rivastigmine, a prescription cholinesterase inhibitor developed by Novartis for treating mild-to-severe Alzheimer's disease and Parkinson's disease dementia. Available as capsules, oral solution, and transdermal patch.

neurologyalzheimersdementia

Competitive Analysis

Market Positioning: Nurtec ODT competes with 1 brands in the same categories, ranging from mass market to luxury positioning.

Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.

Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.

Independent Alternatives to Nurtec ODT

Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.

BootsHealthcare Pharmaceuticals

Boots

Owned by Walgreens Boots Alliance

Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.

pharmacyhealth-beautyuk-retail
Privately Owned

Boots is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.

Duane ReadeHealthcare Pharmaceuticals

Duane Reade

Owned by Walgreens Boots Alliance

Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.

pharmacydrugstorenew-york
Privately Owned

Duane Reade is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.

Pharmacy DirectHealthcare Pharmaceuticals

Pharmacy Direct

Owned by Chempro Chemists

Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.

online-pharmacymail-orderdigital-health
Privately Owned

Pharmacy Direct is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.

RetavaseHealthcare Pharmaceuticals

Retavase

Owned by EKR Therapeutics, Inc.

Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.

pharmaceuticalthrombolyticreteplase
Privately Owned

Retavase is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.

TirosintHealthcare Pharmaceuticals

Tirosint

Owned by IBSA Institut Biochimique S.A.

IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.

levothyroxinehypothyroidismthyroid
Privately Owned

Tirosint is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.

WalgreensHealthcare Pharmaceuticals

Walgreens

Owned by Walgreens Boots Alliance

Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.

pharmacydrugstoreretail-pharmacy
Privately Owned

Walgreens is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.

Pfizer Inc. Stock Information

Jobs at Pfizer Inc.

Latest News About Nurtec ODT

Related Articles About Nurtec ODT

View more articles
Brands That Relocated Headquarters for Tax Reasons
Industry Analysis

Brands That Relocated Headquarters for Tax Reasons

From Pfizer's failed Irish inversion to ExxonMobil's Texas move, discover why brands relocate their headquarters for tax and legal reasons — and how it affects their brand portfolios. Explore our database.

Who Brands StaffMay 22, 2026
TaxHeadquartersCorporate Relocation
How Government Policy Shapes Brand Ownership
Industry Analysis

How Government Policy Shapes Brand Ownership

From antitrust rulings to tariff wars, government policy determines which brands get acquired, which get blocked, and which stay independent. Our guide explains how policy shapes brand ownership. Explore our database.

Who Brands StaffMay 17, 2026
GovernmentPolicyAntitrust
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Brand Comparisons

Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared

Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.

Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
View more articles

People Also Searched

Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase
Brandpharmaceutical

Abbokinase

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Abrysvo
Brandrsv-vaccine

Abrysvo

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Accutane
Branddermatology

Accutane

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Browse All Healthcare & Pharmaceuticals

Last reviewed: September 25, 2026 · Reviewed by Who Brands Editorial Team